Welcome to our dedicated page for MYOMO SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MYOMO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MYOMO's regulatory disclosures and financial reporting.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received a grant of 16,666 shares of Common Stock in the form of Restricted Stock Units (RSUs). This award comes under a program allowing employees to forego 10% of their salary for three months in exchange for RSUs with a grant date fair value equal to 115% of the salary exchanged. The RSUs vest in full on July 9, 2026. After this grant, Gudonis directly holds 1,277,316 shares of the company’s common stock.
MYOMO, INC. Chief Financial Officer David A. Henry reported routine equity compensation and related tax withholding transactions in company stock. He received 12,500 Restricted Stock Units under a board-approved program where employees exchange 10% of three months of salary for RSUs valued at 115% of the salary given up. These RSUs vest in full on July 9, 2026. On April 13, 2026, 3,953 shares of common stock at $0.71 per share were disposed of solely to pay income taxes on restricted stock units that vested on April 12, 2026, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, he directly holds 445,174 shares of Myomo common stock.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis acquired 19,395 shares of common stock through a grant of Restricted Stock Units (RSUs) with no cash paid per share. These RSUs were issued under a program allowing employees to exchange 10% of their salary for equity at a grant date fair value of 115% of the salary given up, covering three months of salary.
The RSUs from this grant vest in full on July 9, 2026. After this award, Gudonis directly holds a total of 1,280,045 shares of Myomo common stock, underscoring that this is primarily a compensation-related equity grant rather than an open‑market purchase.
MYOMO, INC. director Heather C Getz reported an open-market purchase of company stock. On March 16, 2026, she bought 20,000 shares of Myomo common stock at $0.6986 per share, in a single open-market transaction. Following this trade, her direct ownership increased to 131,754 shares of common stock.
MYOMO, INC. director Kirk Thomas F reported an open-market purchase of 72,000 shares of Common Stock. The weighted average purchase price was about $0.7099 per share, with individual trade prices ranging from $0.70 to $0.71. Following these purchases, he directly owns 553,857 shares.
MYOMO, INC. director Heather C. Getz made an open-market purchase of 70,000 shares of common stock at a weighted average price of $0.728 per share. The trades were executed in multiple lots between $0.72 and $0.73 per share.
Following this transaction, she directly owns 111,754 shares of MYOMO common stock. The filing describes these transactions as open-market purchases, indicating she used personal capital to increase her direct equity position in the company.
Myomo, Inc. is a wearable medical robotics company focused on its MyoPro myoelectric upper-limb orthosis, sold mainly through direct billing to patients and their insurers. Revenue grew 26% in 2025 as the company improved cycle times and moved more units from authorization to delivery within each period.
The reimbursement pipeline reached 1,528 patients as of December 31, 2025, up 10% year over year, while backlog declined to 199 MyoPro units, down 27% as cases converted to revenue. Myomo relies heavily on Medicare: patients with Medicare Part B accounted for 54% of total revenue in 2025, and Medicare Advantage plans 20% of product revenue.
CMS pays lump-sum fees under brace codes L8701 and L8702, with 2026 schedule amounts of about $34,970 for Motion W and $68,800 for Motion G. Despite revenue growth, Myomo reported a 2025 net loss of $15.6 million versus $6.2 million in 2024, with an accumulated deficit of about $118.1 million and $18.4 million of cash, cash equivalents and short-term investments at year-end. As of March 2, 2026, 38,511,715 shares of common stock were outstanding.
Myomo, Inc. reported fourth quarter 2025 revenue of $11.4 million, down 6% from 2024, while full-year 2025 revenue grew 26% to $40.9 million. Q4 gross margin was 68.6%, and full-year gross margin was 65.7%, both below 2024 levels.
The company’s net loss widened to $3.8 million in Q4 2025 and $15.6 million for the year, compared with losses of $0.3 million and $6.2 million in 2024. Cash, cash equivalents and short-term investments totaled $18.4 million as of December 31, 2025.
Recurring patient sources, including O&P providers and referrals from the MyoConnect program, accounted for 42% of Q4 revenue versus 26% a year earlier, supported by a record 241 MyoPro orders. For 2026, Myomo expects revenue of $43 million to $46 million and aims to cut negative free cash flow by roughly half compared with 2025.
Myomo, Inc. received an amended Schedule 13G from investment firm Rosalind Advisors, Inc., its fund Rosalind Master Fund L.P., and principals Steven Salamon and Gilad Aharon. They report beneficial ownership of 3,839,772 Myomo common shares, or about 9.99%, based on 38,435,524 shares outstanding as of November 3, 2025.
The group also holds pre-funded warrants for an additional 3,763,258 shares, but a 9.99% ownership blocker prevents exercising these warrants while their stake is at that level. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Myomo.